AbbVie's Duopa successor in Parkinson's rejected again after FDA flags third-party manufacturer issues
Fierce Pharma
JUNE 25, 2024
A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established fo | A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa.
Let's personalize your content